<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Two types of antineutrophil cytoplasmic antibodies (<z:chebi fb="0" ids="34507">ANCA</z:chebi>), antiproteinase 3 antibodies (anti-PR3) and antimyeloperoxidase antibodies (anti-MPO), are useful in the diagnosis of such types of <z:hpo ids='HP_0002633'>vasculitis</z:hpo> as Wegener <z:hpo ids='HP_0002955'>granulomatosis</z:hpo> and <z:e sem="disease" ids="C0343192" disease_type="Disease or Syndrome" abbrv="">microscopic polyangiitis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">Connective tissue diseases</z:e> frequently appear in the differential diagnosis of this spectrum of <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To determine the prevalence of <z:chebi fb="0" ids="34507">ANCA</z:chebi> in patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Blinded, controlled study of a 5-year inception cohort </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: Tertiary-care university teaching hospitals </plain></SENT>
<SENT sid="5" pm="."><plain>PATIENTS: 70 patients with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, 70 patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, 45 patients with <z:hpo ids='HP_0100324'>scleroderma</z:hpo>, 36 patients with inflammatory <z:hpo ids='HP_0100614'>myositis</z:hpo>, 44 patients with the <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">sj√∂gren</z:e> syndrome, 33 patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, and 165 patients with early <z:e sem="disease" ids="C0409999" disease_type="Disease or Syndrome" abbrv="">undifferentiated connective tissue disease</z:e> (EUCTD) </plain></SENT>
<SENT sid="6" pm="."><plain>Serum was taken from 200 blood donors and 52 patients who had known <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and positive results on tests for anti-PR3 or anti-MPO; these patients served as controls </plain></SENT>
<SENT sid="7" pm="."><plain>MEASUREMENTS: The presence of anti-PR3 and anti-MPO was determined by combining the results of indirect immunofluorescence tests for cytoplasmic (C-<z:chebi fb="0" ids="34507">ANCA</z:chebi>) and perinuclear (P-<z:chebi fb="0" ids="34507">ANCA</z:chebi>) patterns with the results of enzymelinked immunosorbent assays (ELISAs) directed to measure antigen </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Cytoplasmic <z:chebi fb="0" ids="34507">ANCA</z:chebi> was not detected in any study or control patient </plain></SENT>
<SENT sid="9" pm="."><plain>Perinuclear <z:chebi fb="0" ids="34507">ANCA</z:chebi> was commonly detected among patients with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> (31%) but was uncommon among patients in other groups (0% to 5%) </plain></SENT>
<SENT sid="10" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases, P-<z:chebi fb="0" ids="34507">ANCA</z:chebi> was associated with the presence of <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Atypical <z:chebi fb="0" ids="34507">ANCA</z:chebi> immunofluorescence patterns were fairly common in <z:hpo ids='HP_0000001'>all</z:hpo> groups (11% to 39%) </plain></SENT>
<SENT sid="12" pm="."><plain>Antiproteinase 3 was detected by ELISA in study patients (1 patient with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, 1 with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>, 1 with <z:e sem="disease" ids="C0085655" disease_type="Disease or Syndrome" abbrv="">polymyositis</z:e>, and 6 with EUCTD) </plain></SENT>
<SENT sid="13" pm="."><plain>Antimyeloperoxidase was detected by ELISA in 2 study patients (1 with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> and 1 with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>) </plain></SENT>
<SENT sid="14" pm="."><plain>None of the patients with positive ELISA results had evidence of renal <z:hpo ids='HP_0002633'>vasculitis</z:hpo> during follow-up </plain></SENT>
<SENT sid="15" pm="."><plain>When an <z:chebi fb="0" ids="34507">ANCA</z:chebi> scoring system that combines immunofluorescence and ELISA was used, the test specificity for <z:hpo ids='HP_0002633'>vasculitis</z:hpo> was 99.5% among patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSIONS: Patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> are known to develop multiple autoantibodies; positivity for anti-PR3 and anti-MPO <z:chebi fb="0" ids="34507">ANCA</z:chebi> in such patients is highly specific for anti-PR3 </plain></SENT>
<SENT sid="17" pm="."><plain>However, P-<z:chebi fb="0" ids="34507">ANCA</z:chebi> immunofluorescence, which may have positive results because of the presence of <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo>, is not a specific marker of anti-MPO </plain></SENT>
<SENT sid="18" pm="."><plain>A rigorous <z:chebi fb="0" ids="34507">ANCA</z:chebi> testing system that combines the results of immunofluorescence with those of ELISA is highly specific for Wegener <z:hpo ids='HP_0002955'>granulomatosis</z:hpo> and related <z:e sem="disease" ids="C0042384" disease_type="Disease or Syndrome" abbrv="">vasculitides</z:e> even in patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> </plain></SENT>
</text></document>